SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs demonstration of a real-time quantum error-correction decoder running on a standard CPU is driving attention, with bullish traders viewing it as progress toward fault-tolerant computing. Others caution that the results are simulation-based rather than a demonstration on a working quantum system, and question whether the announcement represents a practical breakthrough.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX surged on positive VK2735 obesity-drug data showing patients retained much of their weight loss with less-frequent maintenance injections, alongside continued weight loss in the weekly-treatment group. Many traders welcomed the results and speculated about a short squeeze or potential acquisition, while others questioned the muted share-price follow-through and cited competition, early-stage evidence, and possible dilution risks.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

Uncertainty over ASTs satellite deployment is dominating discussion, with traders seeking updates on BlueBird 11s array status and the next satellite shipments and launch dates. Some interpret tracking data as a possible sign of deployment, but it is unconfirmed; others cite the lack of updates, delayed constellation timeline, and cash-burn risk as evidence of execution concerns.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

PENGUs sharp rally and move above the one-cent level are driving attention, with traders debating resistance and whether momentum can continue. One post points to a LINE FRIENDS partnership and growth in Asia, but the broader discussion centers on price action and bullish speculation.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

A Hunterbrook report suggesting Innodata may be helping Meta train its Muse AI assistantand disclosing a long position in the stocksparked attention and a sharp rally. Traders see a possible AI-revenue catalyst, but debate the unconfirmed link and whether the move reflects speculation, a technical breakout, or a short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on Trump TVs launch amid White House press-access restrictions, with traders sharing claims of sharply declining viewership and mocking it as a setback for the companys media ambitions. The conversation is largely critical, though some defend the administrations approach to media coverage.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on the pending final analysis of SELLASs Phase 3 REGAL trial of GPS in AML, with traders watching for the trials 80th death event and a data update. Bulls interpret the prolonged wait as a possible sign of longer survival and speculate about a buyout or short squeeze, while skeptics say the blinded results are unknown; upcoming SLS009 poster presentations are another point of interest.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions Quantum World Congress keynote and its Capitol Hill quantum dinner are drawing attention, with traders speculating about possible technical or partnership announcementsincluding a 30-logical-qubit milestonethough those developments are unconfirmed. Optimism is also being fueled by sympathy with IonQs quantum-computing news, while some traders question whether INFQ can sustain its volatile rally without company-specific news.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Waves finalized U.S. Commerce Department CHIPS Act funding agreement, which includes issuing shares for a minority government stake, has drawn attention and helped lift quantum stocks as a group. Traders are split between viewing the backing as validation and a source of development funding, and worrying that the share issuance will dilute existing holders; subsequent trading has been volatile.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results and raised outlook are being weighed against founder CEO Amnon Shashuas planned transition, with traders debating whether leadership uncertainty outweighs the operating progress. Frustration over the slow pace of the authorized buyback adds to concerns about the share-price weakness, while bulls point to autonomous-driving and robotics opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologyPR NewswireBOSTON, Sept...

TransCode Therapeutics Announces Leadership Transition

TransCode Therapeutics Announces Leadership Transition TransCode Therapeutics Announces Leadership Transition PR Newswire BOSTON, Sept. 10, 2026 Tom Fitzgerald, Chief Financial Officer, Announces his RetirementJohn Tattory, to become Interim Chief Financial OfficerBOSTON, Sept. 10, 2026...

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis PR Newswire...

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million.
TransCode Therapeutics (NASDAQ:RNAZ)read more...

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

TransCode Therapeutics to Host R&D Webcast on June 18, 2026 TransCode Therapeutics to Host R&D Webcast on June 18, 2026 PR Newswire BOSTON, June 8, 2026 Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment ThesisBOSTON, June 8, 2026 /PRNewswire/ -- TransCode...

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer PR Newswire...

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer PR Newswire BOSTON, May 27, 2026 BOSTON, May 27, 2026...

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University TransCode Therapeutics Appoints Dr. Anna...

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 TransCode Therapeutics Enters into Agreements for up to...

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer P

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the...

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

Equity

Neutral Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Current Price	$1.77
Prev Close	$1.76
Open	$1.87
Dividend Yield	0.00%
50-Day Moving Average	$3.86
Beta	2.16
Avg. Volume	77,061.60
PE Ratio	-0.03

52-Week High	$20.99
52-Week Low	$1.58
Market Capitalization	$29.8M
EPS (Annual)	-$52.59
Price to Book	-0.06
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

RNAZ Fundamentals